Kazakova M H, Staneva D N, Koev I G, Staikov D G, Mateva N, Timonov P T, Miloshev G A, Sarafian V S
Department of Medical Biology, Faculty od Public Health Medical University-Plovdiv, Plovdiv, Bulgaria.
Laboratory of Yeast Molecular Genetics, Institute of Molecular Biology "Acad. Roumen Tsanev", Bulgarian Academy of Sciences, Sofia, Bulgaria.
Folia Biol (Praha). 2014;60(6):261-7. doi: 10.14712/fb2014060060261.
Malignant gliomas are the most common type of primary malignant brain tumours, characterized by extreme proliferation and aggressive invasion. There is evidence for over-expression of the YKL40 gene in high-grade gliomas. The high serum levels of the glycoprotein are associated with poor prognosis of various inflammatory and tumour processes. We investigated the YKL40 mRNA level and protein expression in the tumour site and in the serum of high-grade glioma patients. The YKL-40 expression in 36 patients with glial tumours (astrocytoma grade III, glioblastoma) and 33 age-matched healthy persons was measured by gene analysis, immunohistochemistry and ELISA. YKL-40 serum levels in high-grade glioma patients compared to healthy subjects were significantly increased (P ≤ 0.05). A wide range of variability in YKL40 mRNA expression was found. YKL-40 staining in situ was more abundant in glioblastoma tissue than in anaplastic astrocytoma, with the lowest level in normal brain tissue. Our gene analysis revealed that in general, YKL40 mRNA in glioma patients was over-expressed versus normal brain. A significant correlation between YKL40 transcript and protein levels was observed (P ≤ 0.05). It could be speculated that the YKL-40 protein might contribute to glioblastomas' specific biological characteristics that distinguish them from grade III gliomas. A complex investigation of YKL40 expression was performed at the molecular and cellular levels in human high-grade gliomas. Serum YKL-40 concentrations increased with tumour grade and correlated positively with transcript rate, being the highest in glioblastoma. We provide evidence for a relationship between YKL40 expression and the malignancy of glial tumours.
恶性胶质瘤是最常见的原发性恶性脑肿瘤类型，其特征为极度增殖和侵袭性浸润。有证据表明YKL40基因在高级别胶质瘤中过度表达。这种糖蛋白的高血清水平与各种炎症和肿瘤进程的不良预后相关。我们研究了高级别胶质瘤患者肿瘤部位和血清中的YKL40 mRNA水平及蛋白表达。通过基因分析、免疫组织化学和酶联免疫吸附测定法测量了36例胶质肿瘤患者（间变性星形细胞瘤三级、胶质母细胞瘤）和33例年龄匹配的健康人的YKL-40表达。与健康受试者相比，高级别胶质瘤患者的YKL-40血清水平显著升高（P≤0.05）。发现YKL40 mRNA表达存在广泛的变异性。胶质母细胞瘤组织中的YKL-40原位染色比间变性星形细胞瘤中更丰富，在正常脑组织中水平最低。我们的基因分析表明，总体而言，胶质瘤患者的YKL40 mRNA相对于正常脑过度表达。观察到YKL40转录本与蛋白水平之间存在显著相关性（P≤0.05）。可以推测，YKL-40蛋白可能促成了胶质母细胞瘤区别于三级胶质瘤的特定生物学特征。在人高级别胶质瘤中，在分子和细胞水平上对YKL40表达进行了综合研究。血清YKL-40浓度随肿瘤分级增加而升高，并与转录率呈正相关，在胶质母细胞瘤中最高。我们提供了YKL40表达与胶质肿瘤恶性程度之间关系的证据。
